Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation)

The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated the clinical benefit as well as...

Full description

Saved in:

Bibliographic Details
Published in:	Medicinskij sovet no. 9; pp. 186 - 192
Main Authors:	Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Teplyakova, M. A., Tikhanovskaya, N. M., Lianova, A. A., Storozhakova, A. E., Ryadinskaya, L. A., Kabanov, S. N., Kalabanova, E. A.
Format:	Journal Article
Language:	English Russian
Published:	Remedium Group LLC 19-06-2022
Subjects:	abscopic effect brain metastases checkpoint inhibitors immunotherapy nivolumab non-small cell lung cancer radiation therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated the clinical benefit as well as the long-term effect of these drugs. Currently, the problem of treatment of patients after disease progression against the background of the use of checkpoint inhibitors is relevant. Equally relevant is the issue of choosing the correct and most effective treatment tactics for NSCLC patients with oligoprogression, as well as with abscopal effect. This paper describes a clinical case of a patient with lung adenocarcinoma without driver mutations with PD-L1-positive status, who was treated with nivolumab after second-line chemotherapy for disease progression, and after oligoprogression of the disease into the brain was given stereotactic radiotherapy of metastatic lesion and continued therapy with nivolumab. Partial regression of metastases was achieved with a prolonged effect on the background of continued treatment with nivolumab for 24 months. Tolerability of therapy was satisfactory: no adverse events were observed. The patient retained the result for 1.5 years.
ISSN:	2079-701X 2658-5790
DOI:	10.21518/2079-701X-2022-16-9-186-192